Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report issued on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reissued a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Down 3.1 %

Evogene stock opened at $1.39 on Tuesday. The stock has a market cap of $7.44 million, a P/E ratio of -0.31 and a beta of 1.28. Evogene has a 12 month low of $1.20 and a 12 month high of $9.00. The company’s fifty day simple moving average is $1.51 and its 200-day simple moving average is $1.92.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same period in the prior year, the company posted ($1.30) earnings per share.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene at the end of the most recent reporting period. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.